Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

CAR-T therapy targets autoimmune diseases, but trial never started

NCT ID NCT06869278

Disease control Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study planned to test a new CAR-T cell therapy called LCAR-AIO in adults with relapsed or treatment-resistant neurological autoimmune diseases, including multiple sclerosis and myasthenia gravis. The goal was to check safety and find the right dose. However, the trial was withdrawn before any participants were enrolled, so no data was collected.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LCAR-AIO CAR-T cells (a type of genetically modified immune cell)
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-treat autoimmune diseases like multiple sclerosis or myasthenia gravis.
What could go wrong
This trial was withdrawn before enrolling anyone, so no results exist. CAR-T therapy can cause severe side effects, and it is very early-stage research.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Started

Jun 2025

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subjects voluntarily participate in clinical research. 2. Age 18-70 years. 3. Adequate organ function at screening. 4. Clinical laboratory values meet criteria at screening visit. 5. Indications include: MS; 1. Have been diagnosed of MS at least 6 months before screening. 2. Fulfill relapsed/refractory MS conditions. NMOSD/MOGAD: 1. Have been diagnosed of NMOSD/MOGAD at least 6 months before screening. 2. AQP-4 IgG (NMOSD), or MOG-IgG (MOGAD) should be positive by CBA (Cell based transfection immunofluorescence assay). 3. Fulfill relapsed/refractory NMOSD/MOGAD conditions. MG: 1. Have been diagnosed of MG at least 6 months before screening. 2. AChR-IgG or MuSK-IgG should be positive. 3. Fulfill relapsed/refractory NMOSD/MOGAD conditions. Exclusion Criteria: 1. Active infections such as hepatitis and tuberculosis. 2. Other autoimmune diseases. 3. Serious underlying diseases such as tumor, uncontrolled diabetes and clinically significant cardiovascular disease. 4. Female subjects who were pregnant, breastfeeding, or planning to become pregnant while participating in this study or within 1 year of receiving LCAR-AIO treatment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anti-myelin oligodendrocyte glycoprotein-IgG associated disorders (mogad) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

multiple sclerosis myasthenia gravis myelin oligodendrocyte glycoprotein antibody-associated disease neuromyelitis optica Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anti-myelin oligodendrocyte glycoprotein-IgG associated disorders (mogad) Multiple sclerosis (MS) Myasthenia gravis Neuromyelitis optica spectrum disease (nmosd)

Contacts and locations

Locations

  • The Affiliated Hospital of Fujian Medical University

    Fuzhou, China

  • The First Affiliated Hospital of SOOCHOW University

    Suzhou, China

  • Union Hospital Tongji Medical College HUAZHONG University of Science and Technology

    Wuhan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.